News

COVID-19 vaccination had a particularly protective effect in males and those with anxiety or depression.

Adolescent gout rates are rising globally, highlighting the need for early intervention and lifestyle changes to mitigate health risks.

A new meta-analysis reveals aquatic exercise and resistance training as the top therapeutic exercises for reducing fibromyalgia pain in women.

SELARSDI gains FDA interchangeability with Stelara, enhancing access to affordable treatments for psoriatic arthritis, psoriasis, Crohn's, and ulcerative colitis.

An audio recap of the top 5 stories in healthcare news from the week of 04/21-4/27.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and innovative treatments, in this week's essential news roundup for professionals.

This FDA News Month in Review provides a round-up of regulatory decisions from April 2025.

A new study utilizing machine learning reveals how physical activity reduces gout risk in people with hyperuricemia.

New findings highlight the link between fibromyalgia syndrome and increased rates of astigmatism, dry eye disease, and meibomian gland dysfunction.

A recent study reveals a significant prevalence of gout in end-stage renal disease patients, highlighting the complex relationship between kidney function and uric acid levels.

Upadacitinib joins tocilizumab as the second therapy to be approved for treating GCA.

These data suggest promise for dietary interventions and anti-obesity therapies such as incretin-based weight loss medicines for those with psoriatic arthritis (PsA).

3-year interim analysis of the SERENA study confirmed the safety of secukinumab to treat psoriatic arthritis and ankylosing spondylitis.

Pegloticase treatment significantly improves serum urate levels and quality of life in kidney transplant recipients with gout, showing promising clinical benefits.

These preliminary findings on psilocybin-assisted therapy (PAT) for patients with fibromyalgia point to its potential, though additional large-scale research is needed.

Somatization syndromes and childhood trauma emerged as key predictors of fibromyalgia over rheumatoid arthritis in a recent study comparing both groups.

Findings suggest MetS is linked to greater levels of pain catastrophizing in psoriatic arthritis, highlighting the need for multidisciplinary care.

Tumor necrosis factor-α inhibitors are suggested as the optimal treatment for both joint and skin symptoms.

Recent research highlights low certainty in sleep interventions for fibromyalgia, yet exercise shows promise in improving sleep quality.

New findings suggest the 2016 criteria may underdiagnose fibromyalgia in patients with comorbidities, potentially missing the disorder’s full clinical complexity.

New findings refine neuropathic pain treatment guidelines, emphasizing effective medications and the importance of personalized care for improved patient outcomes.

Ten percent of effector genes identified express proteins targeted by approved drugs across disease fields.

Febuxostat was associated with a nearly 3-fold higher risk of mild to moderate perturbation of liver function than benzbromarone.

Investigators call for faster diagnosis and better treatment for psoriatic arthritis to avoid unnecessary complication and suffering.

Participants experienced significant improvements in pain, sleep, and physical function.

Anti-IL-17 medications meant to treat psoriasis and psoriatic arthritis may inadvertently harm gastrointestinal tract.

Significant associations were seen in males, Mexican Americans, married individuals, those with insufficient physical activity, and those with diabetes.

People with ME/CFS also have a high comorbidity rate of fibromyalgia, which has also been seen to improve with aquatic exercise.

More studies are needed to assess whether creatinine or and hyperuricemia may be prognostic factors for these patients.